Search Results
Results 301 - 350 of 1693
< 2 3 4 5 6 7 8 9 10 11 12 >
Masuoka Ayumu - - 2008
In Japan, no pulsatile ventricular assist devices are available specifically for use in children. Pumps designed for adults are thus often used in children. We report herein a case of end-stage heart failure in a 3-year old girl (height 100.4 cm; body weight 16.2 kg; body surface area 0.66 m2) ...
Mussa Shafi - - 2008
Mechanical circulatory support with ventricular assist devices in patients with mechanical valvular prostheses may predispose to thromboembolic and hemodynamic complications. Conventional approaches to reduce these risks involve redo valve replacement to a bioprosthesis. Careful management of the ventricular assist device to allow flow across the prosthesis may obviate the need ...
Westaby Stephen - - 2008
Both prognosis and quality of life are poor for severely symptomatic patients with stage D heart failure, and treatment options are limited. Few individuals are eligible for cardiac transplantation, and ventricular resynchronization therapy provides only marginal benefit in select patients. The aim of this Review is to highlight the promise ...
Sun Benjamin C - - 2008
BACKGROUND: Implantation of ventricular assist devices for cardiac support is normally performed using cardiopulmonary bypass. Post-operative complications could be minimized by the placement of these devices without the use of cardiopulmonary bypass. METHODS: We hypothesize that left ventricular assist devices (LVADs), in selected patients, can be implanted safely off-pump. RESULTS: ...
Matthews Jennifer Cowger - - 2008
This study sought to develop a model that estimates the post-operative risk of right ventricular (RV) failure in left ventricular assist device (LVAD) candidates. Right ventricular failure after LVAD surgery is associated with increased morbidity and mortality, but identifying LVAD candidates at risk for RV failure remains difficult. A prospectively ...
Richards Kyle A - - 2008
Neuromuscular incapacitating devices are used by law enforcement and military forces worldwide. The most frequently used of these devices are from Taser International. Although they are regarded as a less than lethal alternative, there have been several case reports aimed at linking the potential causal relationship of a shock from ...
Aranda Juan M JM - - 2008
The use of investigational passive support devices continues to be evaluated in the treatment of heart failure. One concern with this technology is the future need for a reoperation such as coronary artery bypass surgery, placement of a left ventricular assist device or cardiac transplantation. In this report, we describe ...
Wood Clare - - 2008
In this report we describe the first successful bridge to myocardial recovery with the HeartWare HVAD. Assessment for explantation included serial echocardiography, hemodynamic monitoring, metabolic analysis and manipulation of pump speed, both at rest and during exercise. A protocol for assessing the degree of myocardial recovery without stopping the device ...
Patanè Francesco - - 2008
We present a case of a 71-year-old patient with arterial myocardial revascularization and postoperative course complicated with sternal wound diastasis and subsequent mediastinitis. The patient underwent double revision of the mediastinum: the first in 13th and the second in 27th with total sternectomy. Although the resulting external exposure of pericardial ...
George Isaac - - 2008
OBJECTIVE: Biomaterials and textured surfaces in early pulsatile left ventricular assist devices (HeartMate I; Thoratec Corporation, Pleasanton, Calif) may increase immunologic risk through allosensitization. We hypothesized that axial-flow devices without biologic membranes or textured surfaces (HeartMate II; Thoratec; and DeBakey; MicroMed Cardiovascular, Inc, Houston, Tex) would cause less allosensitization than ...
Long James W - - 2008
OBJECTIVE: Destination therapy experience using long-term left ventricular assist devices was analyzed relative to the benchmark Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure trial to evaluate the potential for improving outcomes with this groundbreaking therapy for advanced heart failure. METHODS: The largest single-center experience with ...
Webb David P - - 2008
Heparin-induced thrombocytopenia paradoxically is a transient pro-thrombotic disorder triggered by heparin exposure. If not treated appropriately, it can be life threatening because of its related thromboembolic complications. In particular, it presents a unique challenge in patients needing extracorporeal life support, because anticoagulation is essential for safe management. This case report ...
Chiam Paul T L - - 2008
We report a case of successful TandemHeart implantation for cardiogenic shock due to critical aortic stenosis using a 21 Fr transseptal cannula which was safely advanced through an existing inferior vena cava (IVC) filter under fluoroscopic guidance. This supported the patient through balloon valvuloplasty and subsequent definitive surgical valve replacement. ...
Osaki Satoru - - 2008
Isolated right heart failure after cardiac surgery is uncommon and the prognosis remains poor. Additionally, managements for these patients are difficult. Profound postcardiotomy right heart failure developed in a 45-year-old woman after aortic root replacement for critical aortic stenosis with small aortic root. Although maximum medical therapy, intraaortic balloon counterpulsation ...
Luo Xin-jin - - 2008
BACKGROUND: Mechanical ventricular assistance is an important therapeutic method for severe heart failure patients. A variety of ventricular assist devices have been designed for use. The purpose of this report was to describe the experience of using Abiomed BVS5000 as a means of left ventricular support as a clinical treatment ...
Sasaki Hideki - - 2008
Acute fulminant myocarditis can cause left ventricular dysfunction that predisposes the patients to critical condition. Left ventricular assist device (LVAD) is a useful option for the patient whose condition is resistant to medical therapy. However, when right ventricular dysfunction with hypoxia is complicated with left ventricular dysfunction, it can be ...
Suyker Willem J L - - 2008
Automated coronary anastomotic devices could be the key to limited or port access procedures. To evaluate their clinical performance to date, 33 studies that included systematic elective angiographic imaging were reviewed, reporting on five proximal and seven distal devices. Marked outcome differences between the technologies were uncorrelated to study type ...
Brieke Andreas - - 2008
Heart failure (HF) is the leading cause of hospital admissions in the United States in people over the age of 65 years. Major advancements in the medical therapy of HF, combined with automatic implantable cardioverter-defibrillators and cardiac resynchronization therapy, have substantially reduced the mortality and morbidity of chronic HF, but ...
Soppa Gopal K R - - 2008
PURPOSE OF REVIEW: There is considerable increase in the use of left ventricular assist devices for the treatment of severe heart failure. Traditionally viewed as a bridge to transplantation and more recently as a destination therapy, left ventricular assist device support is now recognized to offer potential for myocardial recovery ...
Schmitto Jan D - - 2008
We evaluated the newly developed miniaturized HIA microdiagonal blood pump (MDP) as a continuous flow left ventricular assist device. In a sheep model (n = 6), the MDP was implanted through left lateral thoracotomy and placed paracorporeally with inflow conduit to left atrium and outflow conduit to descending aorta. The ...
Onorato Eustaquio - - 2008
Because patent foramen ovale (PFO) represents a lesion which may be repaired a number of expert clinicians believe that mechanical closure should be the primary treatment modality for patients with PFO after cryptogenic stroke; interest has grown on percutaneous devices and in the last years there has been great technological ...
Samuels Louis E - - 2008
The need for a right ventricular assist device following an implantable left ventricular assist device creates a complex situation for the surgeon, nursing staff, and the patient. The purpose of this report is to describe the rationale, technical, and perioperative issues of a hybrid ventricular assist device consisting of a ...
Reade Clifton C - - 2008
We present a young man who sustained an acute myocardial infarction with hemodynamic instability requiring placement of a left ventricular assist device and subsequent cardiac transplantation. Hematologic work-up revealed anti-phospholipid antibody syndrome. To our knowledge this is the first reported case of severe acute heart failure due to anti-phospholipid antibody ...
Rossiter-Thornton Michael - - 2008
We report the first Australian use of the Impella LP 5.0, a minimally invasive, high-output left ventricular assist device. The device was inserted intra-operatively for cardiac failure following coronary artery grafting. Although it facilitated a temporary post-operative recovery, the patient ultimately succumbed due to left ventricular failure more than 30 ...
Jensen Jens - - 2008
The objectives of this study were to investigate whether the systemic inflammatory response differs, in patients undergoing coronary angiography, among the arterial closure devices FemoStop, AngioSeal, and Perclose. The study is a prospective and randomized study. We measured pre- and postprocedural C-reactive protein (CRP), fibrinogen, and interleukin-6 (IL-6) plasma levels ...
Lango Romuald - - 2008
Severe pulmonary embolism may lead to acute right ventricular failure despite immediate surgical embolectomy, which is regarded as the treatment of choice after recent CABG surgery. We report a case of a patient with massive pulmonary thromboembolism which resulted in acute right ventricular failure following early surgical embolectomy. Pulmonary embolism ...
Lam Kayan - - 2009
We describe a novel axillary approach for insertion and usage of the Impella LP5.0, a low cost micro-axial flow pump, in five patients requiring circulatory support after acute ST-segment elevation myocardial infarction (STEMI). This alternative approach for implantation of the Impella LP5.0 has been proven simple, safe and feasible, and ...
Schmitto J D - - 2008
OBJECTIVE: Although a large variety of animal models for acute ischemia and acute heart failure exist, valuable models for studies on the effect of ventricular assist devices in chronic heart failure are scarce. We aimed to establish a stable and reproducible animal model of chronic heart failure in sheep. METHODS: ...
Ailawadi Gorav - - 2008
Ischemic cardiomyopathy affects an estimated 3 million people in the USA and is the most common cause of heart failure. Traditional operations have included heart transplantation, myocardial revascularization, mitral valve repair, left ventricular reconstruction, first-generation left ventricular assist devices and cardiac resynchronization therapy. These operations have become safer in recent ...
Hermansen Stig Eggen - - 2008
OBJECTIVES: The most severe forms of acute heart failure have a dismal prognosis despite modern invasive treatment. For some of these patients, improved outcome must relay on early institution of ventricular assist devices (VAD). We aimed to estimate the potential VAD need in acute heart failure. DESIGN: All patients admitted ...
Russo Pierantonio - - 2008
Mechanical circulatory support can be used to manage acute and chronic cardiac failure in both adult and pediatric patients. Traditionally, extracorporeal membrane oxygenation (ECMO) has been the most common form of mechanical circulatory support in children. However, more recently, in cases of pure ventricular dysfunction, ventricular assist devices (VADs) have ...
Toggweiler Stefan - - 2008
In patients with left ventricular output failure, the Impella left ventricular assist device increases total cardiac output despite a drop in output provided by the left ventricle itself. We present a patient with cardiogenic shock after myocardial infarction in whom an Impella recover 2.5 was implanted. Correct placement was ensured ...
Furukawa Nobuyuki - - 2008
A 66-year-old man with acute fulminant myocarditis was supported by a left ventricular assist device (LVAD) for 22 days, and successfully recovered from severe heart failure. Prior to this, he was treated using percutaneous cardiopulmonary support (PCPS) for five days. However, cardiac function was not recovered, so we conducted implantation ...
Kartha V - - 2008
Left ventricular assist devices (LVADs) provide mechanical support for left ventricular ejection in the failing heart. We describe the anaesthetic management of a patient with an LVAD requiring laparoscopic cholecystectomy. A 51-yr-old female patient with severe heart disease had a Heartmate II LVAD implanted 4 months before this proposed elective ...
Busch Jonas - - 2008
Ventricular support in patients with end-stage heart failure can be achieved using intracorporeal left ventricular assist device (LVAD) or percutaneous ventricular assist device (pVAD) systems. Multiple efforts have been made to minimize procedure-associated complications. We present a case report of an off-pump insertion of a MicroMed DeBakey VAD after Tandem ...
Rathman Lisa - - 2008
Heart failure (HF) is a complex and costly disease process associated with high morbidity and mortality. Implanted cardiac rhythm management devices are increasingly used in the HF population to provide therapies such as protection from sudden death and cardiac resynchronization therapy. Device-based diagnostic monitoring provides clinicians with information that can ...
Garcia Santiago - - 2008
BACKGROUND: In patients with end-stage heart failure, the use of left ventricular assist devices (LVADs) has improved clinical outcomes. Although newer continuous-flow devices have significant advantages, the effect of continuous flow on left ventricular unloading and hemodynamics is less well established. The aim of this investigation was to compare the ...
Yoda Masataka - - 2008
Cardiac retransplantation is controversial therapy because of a chronic shortage of donor hearts. We retrospectively reviewed short- and long-term outcomes after cardiac retransplantation. Between February 1989 and December 2004, 28 cases of cardiac retransplantation were performed. Indications for retransplantation were primary graft failure (PGF) in 11 patients (39.3%), intractable acute ...
Klotz Stefan - - 2008
With improved technology and expanding indications for use, left ventricular assist devices (LVADs) are assuming a greater role in the care of patients with end-stage heart failure. Following LVAD implantation with the intention of bridge to transplant, it became evident that some patients exhibit substantial recovery of ventricular function. This ...
Apostolidou Ioanna - - 2008
We present a patient with end-stage heart failure and heparin-induced thrombocytopenia Type II, who required cardiopulmonary bypass (CPB) during a repeat implantation of a left ventricular assist device for long-term circulatory support. Bivalirudin was selected for anticoagulation during CPB, with concomitant infusion of aprotinin, in an effort to ameliorate blood ...
Tjan T D T - - 2008
We describe the case of a 39-year-old woman who received a self-made total artificial heart built of components from the Thoratec and ExCor Berlin Heart systems. The patient had a severe aortic/myocardial infection following replacement of the ascending aorta with a Shelhigh conduit due to type A aortic dissection. The ...
Bruggink, A.H.
This thesis describes a study of the changes in the extracellular matrix (ECM) of the myocardium, in patients with end stage heart failure and during mechanical support (Left Ventricular Assist Device support, LVAD) of the left ventricle. The changes during LVAD support may lead to recovery of the heart. Chapter ...
Nwaejike Nnamdi - - 2008
Cardiopulmonary bypass (CPB) allows operations on the heart in a motionless and bloodless field while reducing cardiac workload and sustaining systemic and coronary perfusion. Failure to wean from CPB remains a significant problem. Results from recent large registry data have shown dramatic improvement in the survival following ventricular assistance for ...
Morris Rohinton J - - 2008
End-stage congestive heart failure remains the leading cause of death in the United States. Despite advances in medical treatment, it also remains the most common reason for admission to the hospital. The gold standard of treatment for the failing heart, orthotopic heart transplantation, is limited by a shortage of donor ...
Morris Cullen D - - 2008
For patients with end-stage heart failure and contraindications to transplantation, insertion of a continuous-flow left ventricular assist device (LVAD) is an effective treatment strategy. We present a case of LVAD insertion in a 46-year-old man with cyanotic complex congenital heart disease and an extensive surgical history who presented with failure ...
Arora U - - 2008
Ochrobactrum anthropi is an emerging opportunist pathogen in immunocompromised patients. We report a case of septicaemia due to O. anthropi in an elderly male patient with coronary artery disease with severe left ventricular dysfunction admitted in the Intensive coronary care unit. Following intraaortic balloon pump (IABP) insertion, the patient developed ...
Kale Parag - - 2008
The optimal management strategy for patients with acutely decompensated heart failure has been limited to the use of various pharmacologic agents. However, with technological advances in mechanical devices, nonpharmacologic approaches now are available to supplement pharmacologic management. These devices range in sophistication and expertise and target various features of the ...
Hoashi Takaya - - 2008
The criteria for device removal and prediction of sustained recovery are still unclear in the bridge to myocardial recovery strategy using the left ventricular assist system (LVAS). We report the case of an 11-year-old boy with dilated cardiomyopathy, who was successfully weaned off LVAS after 4 months of support. Although ...
Idelchik Gary M - - 2008
BACKGROUND: For patients with persistent cardiogenic shock refractory to intraaortic balloon pump (IABP) support, there are only limited means of resuscitation and bridging to surgical left ventricular assist device (LVAD) implantation. Extracorporeal membrane oxygenation and emergency surgical approaches have been attempted but are associated with significant morbidity and mortality. We ...
Pagani Francis D - - 2008
Left ventricular assist device (LVAD) therapy has become an established treatment option for patients with advanced heart failure. Broader application of this therapy has been limited by the risk profile of the current generation of devices. The development of continuous-flow rotary pump technology with noncontact bearing design offers the promise ...
< 2 3 4 5 6 7 8 9 10 11 12 >